Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain.

Sałat K, Librowski T, Nawiesniak B, Gluch-Lutwin M.

Neurol Res. 2013 Nov;35(9):948-58. doi: 10.1179/1743132813Y.0000000236. Epub 2013 Jul 1.

PMID:
23816319
2.

Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice.

Sałat K, Cios A, Wyska E, Sałat R, Mogilski S, Filipek B, Więckowski K, Malawska B.

Pharmacol Biochem Behav. 2014 Jul;122:173-81. doi: 10.1016/j.pbb.2014.03.025. Epub 2014 Apr 12.

PMID:
24726707
3.

The application of support vector regression for prediction of the antiallodynic effect of drug combinations in the mouse model of streptozocin-induced diabetic neuropathy.

Sałat R, Sałat K.

Comput Methods Programs Biomed. 2013 Aug;111(2):330-7. doi: 10.1016/j.cmpb.2013.04.018. Epub 2013 May 18.

PMID:
23693136
4.

The antiallodynic action of pregabalin may depend on the suppression of spinal neuronal hyperexcitability in rats with spared nerve injury.

Ding L, Cai J, Guo XY, Meng XL, Xing GG.

Pain Res Manag. 2014 Jul-Aug;19(4):205-11. Epub 2014 May 21.

5.

Influence of analgesic active 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one on the antioxidant status, glucose utilization and lipid accumulation in some in vitro and ex vivo assays.

Sałat K, Głuch-Lutwin M, Nawieśniak B, Gawlik K, Pawlica-Gosiewska D, Witalis J, Kazek G, Filipek B, Librowski T, Więckowski K, Solnica B.

Toxicol Mech Methods. 2014 Mar;24(3):204-11. doi: 10.3109/15376516.2013.879973. Epub 2014 Jan 17.

PMID:
24392931
6.

3-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one and pregabalin attenuate tactile allodynia in the mouse model of chronic constriction injury.

Sałat K, Witalis J, Zadrożna M, Sołtys Z, Nowak B, Filipek B, Więckowski K, Malawska B.

Toxicol Mech Methods. 2015;25(7):514-23. doi: 10.3109/15376516.2015.1034333. Epub 2015 May 21.

PMID:
25996035
7.

Dosing time-dependent changes in the analgesic effect of pregabalin on diabetic neuropathy in mice.

Akamine T, Koyanagi S, Kusunose N, Hashimoto H, Taniguchi M, Matsunaga N, Ohdo S.

J Pharmacol Exp Ther. 2015 Jul;354(1):65-72. doi: 10.1124/jpet.115.223891. Epub 2015 May 11.

8.
9.

[Pregabalin--profile of efficacy and tolerability in neuropathic pain].

Stump P.

Drugs Today (Barc). 2009 Oct;45 Suppl C:19-27. Portuguese.

PMID:
20087482
10.

Repeated Dosing with NCX1404, a Nitric Oxide-Donating Pregabalin, Re-establishes Normal Nociceptive Responses in Mice with Streptozotocin-Induced Painful Diabetic Neuropathy.

Varani K, Vincenzi F, Targa M, Ravani A, Bastia E, Storoni L, Brambilla S, Almirante N, Impagnatiello F.

J Pharmacol Exp Ther. 2016 May;357(2):240-7. doi: 10.1124/jpet.115.230193. Epub 2016 Feb 23.

11.

A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.

Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J.

BMC Neurol. 2011 Jan 20;11:7. doi: 10.1186/1471-2377-11-7.

12.

Face-to-face comparison of the predictive validity of two models of neuropathic pain in the rat: analgesic activity of pregabalin, tramadol and duloxetine.

Le Cudennec C, Castagné V.

Eur J Pharmacol. 2014 Jul 15;735:17-25. doi: 10.1016/j.ejphar.2014.04.003. Epub 2014 Apr 12.

PMID:
24726848
13.

A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin.

Zin CS, Nissen LM, O'Callaghan JP, Duffull SB, Smith MT, Moore BJ.

J Pain. 2010 May;11(5):462-71. doi: 10.1016/j.jpain.2009.09.003. Epub 2009 Dec 3.

PMID:
19962354
14.

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain.

Quilici S, Chancellor J, Löthgren M, Simon D, Said G, Le TK, Garcia-Cebrian A, Monz B.

BMC Neurol. 2009 Feb 10;9:6. doi: 10.1186/1471-2377-9-6.

15.

Orofacial sensory changes after streptozotocin-induced diabetes in rats.

Nones CF, Reis RC, Jesus CH, Veronez DA, Cunha JM, Chichorro JG.

Brain Res. 2013 Mar 21;1501:56-67. doi: 10.1016/j.brainres.2013.01.002. Epub 2013 Jan 8.

PMID:
23313875
16.

6-Methoxyflavanone attenuates mechanical allodynia and vulvodynia in the streptozotocin-induced diabetic neuropathic pain.

Akbar S, Subhan F, Karim N, Shahid M, Ahmad N, Ali G, Mahmood W, Fawad K.

Biomed Pharmacother. 2016 Dec;84:962-971. doi: 10.1016/j.biopha.2016.10.017. Epub 2016 Oct 17.

PMID:
27764759
17.
18.

Secoisolariciresinol diglycoside, a flaxseed lignan, exerts analgesic effects in a mouse model of type 1 diabetes: Engagement of antioxidant mechanism.

Hu P, Mei QY, Ma L, Cui WG, Zhou WH, Zhou DS, Zhao Q, Xu DY, Zhao X, Lu Q, Hu ZY.

Eur J Pharmacol. 2015 Nov 15;767:183-92. doi: 10.1016/j.ejphar.2015.10.024. Epub 2015 Oct 19.

PMID:
26494631
20.

Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats.

Ulugol A, Karadag HC, Tamer M, Firat Z, Aslantas A, Dokmeci I.

Neurosci Lett. 2002 Aug 9;328(2):129-32.

PMID:
12133572

Supplemental Content

Support Center